Neuropathy

This comprehensive study, available on PubMed Central, examines the potential of targeting endocannabinoid degradation enzyme inhibitors for the development of new antipsychotic medications. Schizophrenia and other psychotic disorders often lack effective treatments with minimal side effects, driving the need for innovative approaches. The endocannabinoid system, known for its role in Read more…

Schizophrenia and related psychotic disorders pose significant challenges in contemporary psychiatry, necessitating the exploration of novel therapeutic approaches. Recent research has turned towards the endocannabinoid system and its role in psychiatric disorders. Notably, endocannabinoid degradation enzyme inhibitors have emerged as potential antipsychotics, promising a new frontier in medicinal chemistry. The Read more…

Cannabidiol (CBD), a non-psychoactive compound found in cannabis, has garnered significant attention due to its potential therapeutic effects across a variety of conditions. One of the critical pathways through which CBD exerts these effects is by enhancing anandamide signaling within the endocannabinoid system (ECS). The ECS is a complex cell-signaling Read more…